Vulnerable plaque features and adverse events in patients with diabetes mellitus: a post hoc analysis of the COMBINE OCT-FFR trial
Primary result · LOCEResult — go to the resultHazard ratio 15.2 95% CI 4.53–51.0Authors' conclusion
In DM patients with non-ischaemic lesions, TCFA was the strongest predictor of future LOCE events. However, lesions that present additional OCT-VFs are associated with a higher risk of adverse events than OCT-detected TCFA alone.
Study context
- Population
- Diabetes mellitus (DM) patients with ≥1 non-culprit, non-ischaemic lesions (FFR >0.80) undergoing systematic OCT
- Comparison
- Combinations of OCT vulnerability features vs no OCT-VFs
- Thin-cap fibroatheroma (TCFA)n = 98
- Reduced minimal lumen area (r-MLA)n = 190
- Healed plaque (HP)n = 87
- Complicated plaque (CP)n = 116
- Primary endpoint
- LOCE: cardiac mortality, target vessel MI or clinically driven target lesion revascularisation
- Follow-up
- Up to 5 years
Methodological detailsdouble-blind, international
- Double-blind
- International
Primary result
LOCE
Hazard ratio
15.2
95% CI 4.53–51.0
P < 0.001
By group
HP + r-MLA + CP + TCFA vs No OCT-VFs
HR 15.2 (95% CI 4.53–51.0); P < 0.001
As reported in the abstract
Original publication
Vulnerable plaque features and adverse events in patients with diabetes mellitus: a post hoc analysis of the COMBINE OCT-FFR trial. EuroIntervention. Published 3 June 2024. doi:10.
Summarised from the published abstract; every number is checked against it